A pharmaceutical veteran with 20+ years in research and development, Dr. Zhang gained extensive experience in CNS, oncology, inflammatory and autoimmune diseases through his work at Strategene (an Agilent company), Neurocrine Biosciences and BioDuro. He developed a number of antagonists targeting GPCRs related to Parkinson and depression. CRFR1 antagonists representing the first small molecules targeting class B GPCRs, progressed into clinical phase I and II.At BioDuro, he built a team of 100 scientists and led the integrated medicinal chemistry platform that helped forge a number of collaboration programs with big pharmaceuticals, including Johnson & Johnson, Roche, and Lilly, etc. Dr. Zhang was appointed as a distinguished professor at Soochow University. He is also the author of 50+ scientific papers and inventor of 20+ patents duly registered in U.S and China. Dr. Zhang graduated his BA from Peking University and Ph.D from Rutgers University-the State University of New Jersey.

Dr. HE serves as a chief scientific advisor to Accro Bioscience. Her research and discovery primarily focus on the mechanisms and functions of regulated cell death. Dr. HE has published extensively on scientific journals including Cell, PNAS, Nature Immunology, etc., and has made significant contributions to advance our understanding of the molecular mechanisms and physiological functions of regulated cell death. Dr. HE received many national and provincial awards and recognitions for her outstanding scientific work. She was previously a Professor at Soochow University and is currently a Principal Investigator at Suzhou Institute of Systems Medicine. Dr. HE received her B.S. degree in biotechnology from Zhejiang University and Ph.D. degree in biochemistry from Peking Union Medical College / National Institute of Biological Sciences (Beijing).

Kenneth Gao serves as Senior Vice President of Corporate Development and Strategy at Accro Bioscience, where he oversees business development, corporate strategy, and strategic financing. Prior to Accro, Kenneth most recently served as Vice President of Corporate Development and Alliance Management at Overland Pharmaceuticals, a fully integrated biopharma company backed by Hillhouse Capital. At Overland, he spearheaded business development efforts including multiple global transactions and joint venture creation in the field of biologics, ADCs and cell therapies. Before Overland, Kenneth was Senior Director of Corporate Development and Head of China Operations at Assembly Biosciences, a leading infectious disease biotech focused on HBV cure therapies. Previously, Kenneth held various managerial positions at Becton Dickinson, IMS Health, and UBS AG.Kenneth earned an MBA in Health Sector Management from Duke University and a B.S. in Finance from the State University of New York at Buffalo.

Dr. Wang is a Board Certified Medical Oncologist and Physician of Internal Medicine.

He graduated from Second Military Medical University, and successively served in Shanghai Changzheng Hospital (Second Military Medical University), Brigham and Women's Hospital (Harvard Medical School), James Cancer Hospital (Ohio State University School of Medicine), National Institutes of Health (NIH) and the First Affiliated Hospital (Harbin Medical University), served as professor, Ph.D. supervisor and director of Depart.Oncology. His academic achievements include 46 publications on peer-reviewed medical journals and 6 national/provincial/municipal scientific research grants.After devoted in pharmaceutical and biotechnology companies, Dr. Wang has been leading the global phase 1-3 clinical development of new medicines, throughout the discovery, clinical study design and conduction, particularly expertising in the generation of novel international clinical development strategies, including the exploration of first-in-class targets, differential indications selection as well as the original drug combination strategies for small molecule Onco-targeted, biological Onco-immune together with non-Oncology innovative drugs in China, Australia and US, etc.

Dr. KANG has over 20 years of experience in drug discovery and development. As an expert in preclinical study (pharmacology, DMPK, toxicology), He has led a number of new drug projects for IND fillings that led to approvals by FDA & CDE. Prior to joining Accro Bioscience, Dr. KANG worked as a postdoctoral fellow/research scientist in Chiron Corporation (US) and as a Director of Preclinical Development in Ascentage Pharma.His last role was Vice President of R&D at Hangzhou Converd Co., Ltd. Dr. KANG received his B.S. degree in Cell Biology & Genetics from Peking University, and Ph.D. degree in Microbiology from Michigan State University.

Dr. Ma has engaged in drug discovery and development for more than 10 years and participated in several projects with indications in inflammatory, autoimmune diseases and oncology. He worked in Chempartner Co.,Ltd, Wuxi Pharma Tech, and BioDuro from 2005 to 2012. He got his PhD and worked as a postdoc in Soochow University. He has published 10 papers and is an inventor of over 10 US and Chinese patents.